Bellerophon Therapeutics, Inc. (BLPH)

Bellerophon Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep 25, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Market Capitalization	0	9	29	63	24	47
Market Cap Growth	-53.25%	-70.85%	-53.48%	163.68%	-48.91%	-66.97%
Enterprise Value	-4	-2	2	11	14	26
Last Close Price	0.04	0.90	3.10	6.67	5.25	12.02
PE Ratio	-	-0.43	-1.66	-2.10	-1.78	-2.37
PB Ratio	0.12	3.39	1.36	1.66	6.69	12.20
P/FCF Ratio	-0.39	-0.48	-1.29	-3.19	-1.86	-3.03
P/OCF Ratio	-0.39	-0.48	-1.29	-3.19	-1.86	-3.03
EV/EBITDA Ratio	0.52	0.10	-0.10	-0.43	-0.80	-0.96
EV/EBIT Ratio	0.52	0.10	-0.10	-0.43	-0.78	-0.95
EV/FCF Ratio	0.46	0.13	-0.08	-0.56	-1.06	-1.71
Debt / Equity Ratio	-	0.08	0.04	0.04	0.65	-
Debt / FCF Ratio	-	-0.01	-0.04	-0.08	-0.18	-
Quick Ratio	3.49	1.28	4.90	4.56	1.30	2.21
Current Ratio	3.96	1.40	5.04	4.61	1.37	2.31
Return on Equity (ROE)	-165.96%	-164.21%	-59.32%	-118.20%	-356.30%	445.96%
Return on Assets (ROA)	-78.47%	-80.40%	-32.01%	-51.85%	-69.41%	-63.17%
Return on Capital (ROIC)	-119.52%	-110.57%	-39.51%	-71.69%	-223.69%	-2761.49%
Earnings Yield	-2314.99%	-230.84%	-60.25%	-39.03%	-55.22%	5.98%
FCF Yield	-253.70%	-206.85%	-77.44%	-31.39%	-53.84%	-32.95%
Buyback Yield / Dilution	-16.43%	-0.51%	-21.88%	-73.14%	-3.85%	-67.00%
Total Shareholder Return	-16.43%	-0.51%	-21.88%	-73.14%	-3.85%	-67.00%

Source: S&P Capital IQ. Standard template. Financial Sources.